295 related articles for article (PubMed ID: 28806568)
21. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
Miceli MH; Kauffman CA
Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
[TBL] [Abstract][Full Text] [Related]
22. Liquid chromatography-tandem mass spectrometry for the quantification of moxifloxacin, ciprofloxacin, daptomycin, caspofungin, and isavuconazole in human plasma.
Hösl J; Gessner A; El-Najjar N
J Pharm Biomed Anal; 2018 Aug; 157():92-99. PubMed ID: 29777985
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous quantitation of five triazole anti-fungal agents by paper spray-mass spectrometry.
Skaggs CL; Ren GJ; Elgierari ETM; Sturmer LR; Shi RZ; Manicke NE; Kirkpatrick LM
Clin Chem Lab Med; 2020 Apr; 58(5):836-846. PubMed ID: 31926066
[TBL] [Abstract][Full Text] [Related]
24. Rapid HPLC-MS/MS method for simultaneous quantitation of four routinely administered triazole antifungals in human plasma.
Beste KY; Burkhardt O; Kaever V
Clin Chim Acta; 2012 Jan; 413(1-2):240-5. PubMed ID: 21996080
[TBL] [Abstract][Full Text] [Related]
25. Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials.
Andes D; Kovanda L; Desai A; Kitt T; Zhao M; Walsh TJ
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735569
[TBL] [Abstract][Full Text] [Related]
26. High-throughput identification and determination of antifungal triazoles in human plasma using UPLC-QDa.
Pan L; Fan X; Jia A; Li Y; Zhao Y; Liu Y; Wang A; Ma Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Jul; 1226():123774. PubMed ID: 37329778
[TBL] [Abstract][Full Text] [Related]
27. Measurement of posaconazole, itraconazole, and hydroxyitraconazole in plasma/serum by high-performance liquid chromatography with fluorescence detection.
Buckner SL; Ceesay MM; Pagliuca A; Morgan PE; Flanagan RJ
Ther Drug Monit; 2011 Dec; 33(6):735-41. PubMed ID: 22105591
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS.
Baietto L; D'Avolio A; Marra C; Simiele M; Cusato J; Pace S; Ariaudo A; De Rosa FG; Di Perri G
J Antimicrob Chemother; 2012 Nov; 67(11):2645-9. PubMed ID: 22872447
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
Stott KE; Hope WW
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i12-i18. PubMed ID: 28355463
[TBL] [Abstract][Full Text] [Related]
30. High-throughput simultaneousquantification offive azole anti-fungal agents and one active metabolite in human plasma using ultra-high-performance liquid chromatography coupled to tandem mass spectrometry.
Tanaka R; Shiraiwa K; Takano K; Ogata M; Honda S; Yoshida N; Okuhiro K; Yoshida M; Narahara K; Kai M; Tatsuta R; Itoh H
Clin Biochem; 2022 Jan; 99():87-96. PubMed ID: 34715112
[TBL] [Abstract][Full Text] [Related]
31. Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis.
Höhl R; Bertram R; Kinzig M; Haarmeyer GS; Baumgärtel M; Geise A; Muschner D; Prosch D; Reger M; Naumann HT; Ficker JH; Kubitz J; Steinmann J; Sörgel F
Mycoses; 2022 Jul; 65(7):747-752. PubMed ID: 35535740
[TBL] [Abstract][Full Text] [Related]
32. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation.
Gómez-López A
Clin Microbiol Infect; 2020 Nov; 26(11):1481-1487. PubMed ID: 32535150
[TBL] [Abstract][Full Text] [Related]
33. Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.
Rybak JM; Marx KR; Nishimoto AT; Rogers PD
Pharmacotherapy; 2015 Nov; 35(11):1037-51. PubMed ID: 26598096
[TBL] [Abstract][Full Text] [Related]
34. Experience with therapeutic drug monitoring of three antifungal agents using an LC-MS/MS method in routine clinical practice.
Yoon SJ; Lee K; Oh J; Woo HI; Lee SY
Clin Biochem; 2019 Aug; 70():14-17. PubMed ID: 31175859
[TBL] [Abstract][Full Text] [Related]
35. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
Jenks JD; Salzer HJ; Prattes J; Krause R; Buchheidt D; Hoenigl M
Drug Des Devel Ther; 2018; 12():1033-1044. PubMed ID: 29750016
[TBL] [Abstract][Full Text] [Related]
36. Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS.
Alffenaar JW; Wessels AM; van Hateren K; Greijdanus B; Kosterink JG; Uges DR
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jan; 878(1):39-44. PubMed ID: 19945360
[TBL] [Abstract][Full Text] [Related]
37. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
Ledoux MP; Denis J; Nivoix Y; Herbrecht R
J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
[TBL] [Abstract][Full Text] [Related]
38. Validated liquid chromatography-tandem mass spectroscopy method for the simultaneous quantification of four antimycotic agents in human serum.
Chahbouni A; Wilhelm AJ; den Burger JC; Sinjewel A; Vos RM
Ther Drug Monit; 2010 Aug; 32(4):453-7. PubMed ID: 20526234
[TBL] [Abstract][Full Text] [Related]
39. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
Shivaprakash MR; Geertsen E; Chakrabarti A; Mouton JW; Meis JF
Mycoses; 2011 Sep; 54(5):e583-9. PubMed ID: 21518026
[TBL] [Abstract][Full Text] [Related]
40. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.
Bongomin F; Maguire N; Moore CB; Felton T; Rautemaa-Richardson R
Mycoses; 2019 Mar; 62(3):217-222. PubMed ID: 30570179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
